SCHEMBL29949182

SCHEMBL29949182

Cc1nnc(NCc2cccc(N)c2N)o1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HDAC4 P56524 1/20 0.46
MEF2D Q14814 1/20 0.46
CD44 P16070 1/20 0.34
ELANE P08246 2/20 0.34
KDM4E B2RXH2 3/20 0.32
ALDH1A1 P00352 2/20 0.32
TP53 P04637 2/20 0.32
GAA P10253 2/20 0.32
CSNK2A2 P19784 1/20 0.32
CSNK2B P67870 1/20 0.32
CSNK2A1 P68400 1/20 0.32
CSNK2A3 Q8NEV1 1/20 0.32
LMNA P02545 1/20 0.32
ALOX15 P16050 1/20 0.32
ALOX12 P18054 1/20 0.32
NPC1 O15118 2/20 0.31
RAB9A P51151 2/20 0.31
HSD17B10 Q99714 2/20 0.31
CDC7 O00311 2/20 0.31
CCNE1 P24864 2/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29949172 0.79 CD44 (0.34) HDAC4MEF2DCD44ELANEGAA
SCHEMBL29949337 0.72 EGFR (0.32) CSNK2A2CSNK2BCSNK2A1CSNK2A3
SCHEMBL29949208 0.67 BACE1 (0.35) LMNAHSD17B10MAPTNPSR1
SCHEMBL2993419 0.66 MAOA (0.45) KDM4EALDH1A1TP53GAALMNA
SCHEMBL9687484 0.64 MAPT (0.44) CD44KDM4EALDH1A1NPC1HSD17B10
SCHEMBL595335 0.61 GABRA1 (0.48) CD44ELANEKDM4EALDH1A1ALOX15
SCHEMBL31752918 0.61 NOTUM (0.49) NPC1
Dimethylamine SCHEMBL9706131 0.61 GABRA1 (0.43) CD44ELANEKDM4EALDH1A1GAA
SCHEMBL1257763 0.61 SLC6A4 (0.55) CD44
SCHEMBL3132841 0.61 CD44 (0.46) CD44ALDH1A1ALOX15HSD17B10

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11945811-B2 Potassium channel inhibitors ACESION PHARMA APS (DK) 2024-04-02 US disclosed
CN-117561247-A Novel potassium channel inhibitors 阿塞西翁制药公司 2024-02-13 CN disclosed
EP-4313973-A1 NOVEL POTASSIUM CHANNEL INHIBITORS Acesion Pharma ApS (DK) 2024-02-07 EP disclosed
WO-2022200162-A1 NOVEL POTASSIUM CHANNEL INHIBITORS ACECION PHARMA APS (DK) 2022-09-29 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11945811-B2 Potassium channel inhibitors KCNJ2, KCNN2, KCNN1 HDAC4 673/4885MEF2D 1382/4885CD44 4334/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.